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Purpose: Statins are widely prescribed medications for treatment of dyslipidemia and 
prevention of cardiovascular disease. Beyond their lipid-lowering property, statins exhibit 
multiple pleiotropic and antimicrobial effects. We aimed to investigate the effect of statins on 
the long-term risk of pneumonia after acute ischemic stroke.
Methods: This retrospective observational research was performed using South Korean 
National Health Insurance Service claim data, which consist of population-based random 
sampling. We included patients discharged with acute ischemic stroke (I63 in the ICD10) and 
no prior history of pneumonia. The primary outcome measure was the occurrence of 
pneumonia determined based on ICD10 code J09–J18. Treatment with statins during follow- 
up was collected as a time-dependent variable based on prescription records.
Results: A total of 7,001 subjects with acute ischemic stroke and no prior history of 
pneumonia were included. During the mean 3.96-year follow-up, pneumonia occurred in 
1,715 subjects (24.5%). On multivariate time-dependent Cox proportional hazard–regression 
analyses, significant preventive benefit of treatment with statins against pneumonia was 
noted (adjusted HR 0.86, 95% CI 0.77–0.97). Compared to no use of statin, adjusted 
HRs (95% CIs) for current use of low–intermediate high-intensity statins were 0.88 (0.78–-
0.99) and 0.49 (0.27–0.87), respectively.
Conclusion: Our retrospective national cohort study found reduced risk of poststroke 
pneumonia with statin therapy after acute ischemic stroke. Our study suggests that treatment 
with statins may have a preventive effect against the common complication of poststroke 
pneumonia.
Keywords: statin, pneumonia, infection, stroke
Introduction
Stroke victims are at particularly increased risk of acquiring pneumonia, a critical 
cause of death after stroke.1 Stroke victims frequently experience dysphagia leading 
to aspiration of food and development of pneumonia. Additionally, not only older 
age but also malnutrition and limited physical activity due to stroke are well-known 
risk factors for developing pneumonia.2,3 Because poststroke pneumonia is fatal 
and a marker of worse prognosis,4 identification of risk factors and development of 
preventive strategies for poststroke pneumonia are clinically important in stroke 
victims.5,6
Statins are widely prescribed medications for treatment of dyslipidemia and pre-
vention of cardiovascular disease. Beyond their lipid-lowering property, statins exhibit 
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multiple pleiotropic and antimicrobial effects. Statins can 
affect a variety of immuno responses, including immune- 
cell activation, migration, cytokine production, stimulation 
of antigen-presenting cells, and immune-cell metabolism 
and survival, which are related to protection against infec-
tion or inflammation.7 Owing to statins’ immunomodulating 
effects, prior studies have suggested that treatment with 
them may lower the risk of pneumonia.8,9 There have been 
studies on whether treatment with statins before admission 
or during the acute phase of stroke might reduce the devel-
opment of pneumonia.10,11 However, the findings were 
inconsistent and unclear, and so failed to establish 
a definitive relationship between long-term risk of pneumo-
nia and exposure to statins beyond the acute phase of 
stroke.11 In clinical practice, the use of drugs is dynamic 
and may be frequently changed. The influence of statin 
intensity on the risk of developing pneumonia is not well 
known. Therefore, the current retrospective study was con-
ducted using a Korean national sample cohort data, which 
include longitudinal data regarding the occurrence of pneu-
monia and records of prescription, to evaluate the effects of 




This was a retrospective study based on the random- 
sampling dataset of the South Korean National Health 
Insurance Service claim database.12 This dataset 
is composed of 1,025,340 subjects randomly sampled and 
stratified by age, sex, and earning level. Because the National 
Health Insurance Service in South Korea is a single-payer 
system, overall health claims comprising demographics, hos-
pitals visits, receipt of surgery or procedures, prescriptions, 
diagnosis, and mortality information of the participants 
included were available. Diagnostic codes at each hospital 
visit were recorded based on the ICD10. The National Health 
Insurance database is fully anonymized and does not contain 
any personal identification information. The Institutional 
Review Board of Bundang CHA Medical Center (IRB 
CHAMC 2017–12-043) approved the study and waived the 
requirement for informed consent.
Study Subjects
Patients ≥20 years of age who had been hospitalized 
(visited emergency medical center or admitted to hospital) 
between July 2002 and December 2013 with a main 
diagnosis of ischemic stroke (I63 in ICD10) were 
included. In order to enroll subjects with acute ischemic 
stroke, participants who had undergone brain magnetic 
resonance imaging or computed tomography during hospi-
tal admission were selected, considering that subjects with 
acute ischemic stroke would have had brain imaging 
performed.13 Patients who had ICD10 code of J09–J18 
(pneumonia) prior to discharge date of the index stroke 
were excluded. In South Korea’s health-claim system, the 
previously registered diagnostic code may be automati-
cally registered in the latter visit. Therefore, once the 
pneumonia ICD10 code has been assigned to a patient, it 
is not possible to determine clearly whether the pneumonia 
has been cured or remains in the NHIS-NSC data set. 
When a patient revisits the same hospital, it is ambiguous 
whether the revisit is due to recurrence of pneumonia or 
another medical problem. Therefore, to exclude the 
potency of false positives due to prior diagnosis, we 
included only patients who had not had a prior diagnosis 
of pneumonia (excluding patients with a history of pneu-
monia). Because inclusion of prevalent statin users in the 
observational study may introduce selection bias, patients 
who had exposure to statins within 6 months before the 
admission of acute ischemic stroke were excluded.14,15 To 
detect only patients who newly developed pneumonia after 
stroke as outcome, patients who had less than a month of 
follow-up after discharge were also excluded.16 Flowchart 
of the inclusion and exclusion criteria of patients is shown 
in Figure 1.
Outcome and Follow-Up
The primary outcome measure was the time of occurrence 
of pneumonia, which was considered from hospital-visit 
records with diagnostic codes J09–J18.17,18 Detection of 
pneumonia from ICD10 codes has been reported to be 
reliable and widely used in research data.19,20 All subjects 
were followed up until the occurrence of pneumonia, 
death, loss of eligibility for the South Korean National 
Health Insurance Service, or 31 December, 2013, which-
ever occurred first.
Drug-Exposure Assessment
On each day of follow-up after discharge from the index 
stroke, data on treatment with statins was accessed using 
the prescription records of each patient, which were col-
lected as time-dependent variables. To evaluate the dose– 
response relationship, statin intensity was grouped into 
low– intermediate intensity (atorvastatin <20 mg, 
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rosuvastatin <10 mg, pravastatin ≤80 mg, lovastatin 
≤40 mg, simvastatin ≤40 mg, fluvastatin ≤80 mg, pitavas-
tatin ≤4 mg) and high intensity (atorvastatin ≥40 mg, 
rosuvastatin ≥20 mg) according to the type and daily 
dose of the statins in accordance with the low-density 
lipoprotein–lowering potency of each agent.21
Other Covariates
Other covariates were age, sex, earning level, and comorbid-
ities: hypertension, diabetes mellitus, atrial fibrillation, myo-
cardial infarction, and chronic obstructive pulmonary 
disease. In the NHIS-NSC dataset, age is recorded at 5-year 
intervals for privacy protection. Earning level is stratified 
into tertile groups. Use of thrombolysis (653,500,660, 
653,500,670, E04260071, E04260161 for intravenous and 
M6631, M6632, M6633 for intra-arterial) for acute ischemic 
stroke was determined by the procedure codes in the NHIS- 
NSC. The presence of hypertension (I10–I15), diabetes 
mellitus (E08–E11, E13–E14), atrial fibrillation (I48), myo-
cardial infarction (I21), and chronic obstructive pulmonary 
disease (J42, J43 [not J43.0], J44) were defined by diagnostic 
and procedure codes before or during hospitalization for the 
index stroke.13,22 Hypertension and diabetes mellitus were 
recognized as relevant only if subjects had received antihy-
pertensive or antidiabetic medications at the time of 
diagnosis.23 Stroke severity was considered a possible mar-
ker of prognosis; however, data were unavailable in the 
NHIS-NSC, with limitations in health insurance–claim 
data. Instead, length of hospital stay following index stroke 
was considered an alternative marker, which has proven to be 
Figure 1 Flowchart of patients included. 
Abbreviation: NHIS-NSC, National Health Insurance Service national sample cohort.
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reliably associated with baseline stroke severity and stroke- 
related disability.24 Participants were divided into two groups 
(≤16 days, >16 days) based on median length of hospital stay 
following index stroke. Based on the health-care resources of 
the hospital at index stroke, classification was “general hos-
pital”, which referred to large-scale hospitals, and “clinic or 
hospital”.
Statistical Analyses
Age recorded at 5-year intervals was treated as a continuous 
variable in the statistical analysis and expressed as 
medians and IQRs. Comparison of characteristics between 
the two groups was performed using χ2 tests for categorical 
variables and Mann–Whitney U tests for continuous vari-
ables (age-groups). The use of statins on each day of follow- 
up was considered the time-dependent variable (unit of time 
is day). Plots for estimated pneumonia-free probability 
according to treatment with statins were done considering 
the nature of the time-dependent variable.25 HRs and 95% CI 
were calculated by time-dependent Cox proportional hazard– 
regression models. During follow-up, patients who died 
without pneumonia were treated as censoring events. To 
investigate associative factors for occurrence of pneumonia, 
adjustments were performed for age, sex, earning level, 
history of hypertension, diabetes mellitus, atrial fibrillation, 
myocardial infarction, chronic obstructive pulmonary dis-
ease, use of thrombolysis, and type of hospital at index 
stroke. Linear trends in statin intensity and clinical outcome 
were estimated by regarding the statin-intensity groups as 
a continuous variable (no statins 0, low–intermediate inten-
sity statins 1, and high-intensity statins 2). The proportional- 
hazard assumption for the model was tested by calculating 
Schoenfeld residuals and found to be satisfactory. Data man-
agement and statistical analyses were undertaken with 
R version 3.4.4 (R Foundation for Statistical Computing, 
Vienna, Austria; http://www.R-project.org) and PostgreSQL 
version 10.6 (PostgreSQL Global Development Group; 




The current study included 7,001 subjects discharged after 
acute ischemic stroke without a history of pneumonia 
(Figure 1). The median age was 65–69 years (IQR 55–59 to 
75–79 years), and 55.7% were men (Table 1). Figure 2 shows 
the proportions of participants with current use of statins 
during the follow-up period after stroke. In the figure, the 
proportion of subjects with current use of statins was relatively 
consistent (about 30%) throughout the poststroke period. At 
1 year after discharge from index stroke, 5,640 subjects were 
at risk of developing pneumonia (patients remained and had 
no pneumonia until the time point). Among the 5,640 subjects 
at 1 year postdischarge, 1,386 (24.6%) were current users of 
statins. To identify the difference in characteristics of subjects 
who received statins with those who did not, clinical charac-
teristics were compared between the groups (Table 2). 
Subjects with current use of statins were more likely to be 
male, younger, have hypertension and/or diabetes mellitus, 
have received thrombolysis and been hospitalized in 
a general hospital with longer length of stay in hospital for 
index stroke.
Risk of Pneumonia
During 3.96±2.99 years of follow-up after discharge from 
index stroke, there were 1,715 subjects that developed 
pneumonia (24.5%). Censored patients without pneumonia 
numbered 5,286 (1,218 who had died, 152 with loss of 
eligibility for national health insurance, and 4,068 subjects 
who had survived without pneumonia until the study end 
Table 1 Baseline Characteristics of Patients with Acute Ischemic 
Stroke
n=7,001
Sex, male 3,902 (55.7)
Age, years 65–69 (55–59 to 
75–79)
Hypertension 5,083 (72.6)
Diabetes mellitus 1,862 (26.6)
Myocardial infarction 473 (6.8)
Atrial fibrillation 688 (9.8)






Hospital type at index stroke
General hospital 5,844 (83.5)
Hospital or clinic 1,157 (16.5)
Duration of hospital stay following index 
stroke
≤16 days 3,690 (52.7)
>16 days 3,311 (47.3)
Note: Data presented as n (%) or medians (IQRs).
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date). Figure 3 demonstrates the estimated pneumonia-free 
survival curves according to current treatment with statins 
during the follow-up period. In the plot, subjects who 
received statins had lower risk of pneumonia compared 
to those who did not (unadjusted HR 0.81, 95% CI 0.73–-
0.91; p<0.001; Figure 3A). When subdivision was based 
on statin intensity (low– intermediate and “high”), use of 
both low– intermediate (unadjusted HR (0.83, (95% CI 
0.74–0.94; p=0.002) and high (unadjusted HR (0.45, (95% 
CI 0.25–0.81; p=0.008)–intensity statins was significantly 
associated with lower risk of pneumonia than no use of 
statins (Figure 3B). In the multivariate time-dependent 
Cox proportional hazard–regression model, there was sig-
nificantly lower risk of developing pneumonia with current 
use of statins (adjusted HR 0.86, 95% CI 0.77–0.97; 
p=0.013) than no use of statins (Table 3). Other significant 
risk factors for poststroke pneumonia were male sex, old 
age, diabetes mellitus, chronic obstructive pulmonary dis-
ease, and admission to a hospital or clinic at index stroke.
Risk of Pneumonia According to Statin 
Intensity
In the multivariate model considering statin intensity (Table 4), 
both statin-intensity groups were significantly associated with 
lower risk of poststroke pneumonia. Compared with no statin, 
the risk of pneumonia (adjusted HR [95% CI]) with low- to 
intermediate-intensity statins and high-intensity statins was 
0.88 (0.78–0.99) and 0.49 (0.27–0.87), respectively. There 
was a significant dose–response relationship between statin 
intensity and risk of poststroke pneumonia (p for trend=0.004).
Discussion
Using the national sample cohort based on health insurance– 
claim data in South Korea, we investigated the risk of occur-
rence of pneumonia according to treatment with statins 
throughout the long-term follow-up period after acute 
ischemic stroke. Poststroke pneumonia was common in the 
current study during the mean follow-up of 3.96 years, 
wherein 24.5% of patients suffered it. The chief finding of 
this study was that treatment with statins was significantly 
associated with lower risk of poststroke pneumonia. The 
amplitude of risk reduction with statins (adjusted HR 0.86) 
was comparable with data from prior epidemiological studies 
suggesting a preventive role of statins against pneumonia.26 
In this real-world study on acute ischemic stroke, the propor-
tion of patients who received statin therapy was suboptimal. 
Suboptimal use of statins in the real world, even after major 

































Figure 2 Proportion of patients with current of statin use throughout the poststroke period. The proportion was calculated by dividing the number of patients with current 
statin use by the number of patients still at risk of pneumonia at each time point.
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remains a major challenge in clinical practice.13 As post-
stroke pneumonia is common and associated with short- 
term and long-term disability, attempts should be made to 
prevent development of the condition.10 Data from the cur-
rent study suggest that enhancement of guideline- 
recommended statin therapy after ischemic stroke may 
further reduce the risk of poststroke pneumonia beyond the 
established cardiovascular risk reduction.13
The exact mechanism of action of statins on pneumonia 
remains uncertain. Multiple antimicrobial and immunomodu-
lating mechanisms of statins have been suggested.27 
Experimental and animal studies have indicated that treatment 
with statins results in a protective immunoresponse against 
pathogens and attenuation of tissue injury by proinflammatory 
pathways, independently of lipid-lowering properties.28 There 
are cellular and molecular protective mechanisms of statins in 
cytokine synthesis, adhesive molecules, Toll-like receptors, 
B lymphocytes, and helper and regulatory 
T lymphocytes.29,30 In acute inflammatory states induced by 
exotoxin, pretreatment with simvastatin significantly 
attenuates expression of P-selectin in endothelia, leukocyte 
rolling, adherence, and transmigration of leukocytes.31 The 
statin-mediated interaction between leukocytes and endothelial 
cells may be involved in both inflammatory pathways and 
tissue injury in infectious diseases. In lipopolysaccharide 
(LPS) stimulation, the protein secretion and mRNA expression 
of IL6 and IL8 are significantly inhibited by treatment with 
pitavastatin and pravastatin.32 Atorvastatin attenuates TNFα 
expression and production in LPS-stimulated macrophages.33 
Administration of atorvastatin reduces levels of serum IFNγ 
and IL4 in Candida albicans–infected mice.34 Proliferation 
and activation of T lymphocytes is inhibited by multiple statin- 
mediated mechanisms.35,36 There is evidence of CD4:CD8 
ratio and shift from type 1 to type 2 helper T cells with 
simvastatin.37 These altered immuno responses from statins 
are predominantly anti-inflammatory and immunosuppressive, 
which might be predisposing factors in infection.38 However, 
numerous studies have shown that statins also can induce 
strong proinflammatory responses when costimulatory signals 
are provided.39 In addition, there are experimental data that 
statins can enhance and modulate innate immunity.40,41 In 
macrophages, statins promote autophagy pathways by indu-
cing endosome maturation and fusion of autophagosomes with 
lysosomes, resulting in degradation of sequestered bacteria.42 
Statins have been shown to increase plasma high-density lipo-
protein, which can act as an antioxidative and anti- 
inflammatory molecule that impedes monocyte chemotaxis.43 
Lipoproteins play an important role in immunoresponse.44 
Furthermore, statins may exhibit antibacterial activity that 
interrupts bacterial cell functions via binding and disruption 
of cell-wall structures such as teichoic acids, lipoteichoic acids, 
LPSs, and surface proteins.45 Modulation of gene expression in 
immune cells and cell-adhesion molecules by statins may 
reduce replication of viruses, including influenza.46 By promo-
tion of the host-defense mechanism and inhibition of patholo-
gical inflammation, statins may play a beneficial protective 
role against infectious diseases.27 Along with the theoretical 
background, many epidemiological studies have reported that 
therapy with statins may reduce the risk of pneumonia, infec-
tion, and mortality in the general population and various dis-
ease groups, including stroke.8,10,26,47,48 As supporting data for 
the antibacterial and immunoprotective effects of statins, treat-
ment with statins confers a survival advantage to patients with 
a diagnosis of pneumonia.49 Among thrombolyzed stroke 
patients, continued treatment with statins is negatively asso-
ciated with pneumonia after stroke.10 In cohort studies using 
Taiwan’s National Health Insurance Research Database, statin 
Table 2 Comparison of Characteristics Between Patients with 
Current Use of Statin and Those Without at 1-Year After Acute 
Ischemic Stroke
No use of 
statins 
(n=4,254)




Sex, male 2323 (54.6) 817 (58.9) 0.005
Age, years 65–69 (55–59 
to 75–79)
65–69 (55–59 to 
70–74)
<0.001
Hypertension 2,965 (69.7) 1,046 (75.5) <0.001
Diabetes mellitus 982 (23.1) 435 (31.4) <0.001
Myocardial infarction 268 (6.3) 94 (6.8) 0.567
Atrial fibrillation 369 (8.7) 129 (9.3) 0.505
Chronic obstructive 
pulmonary disease
784 (18.4) 236 (17.0) 0.255
Thrombolysis 114 (2.7) 61 (4.4) 0.002
Household income 0.152
Low 1,409 (33.1) 421 (30.4)
Middle 1,540 (36.2) 515 (37.2)
High 1,305 (30.7) 450 (32.5)
Hospital type at index 
stroke
<0.001
General hospital 3,468 (81.5) 1,264 (91.2)
Hospital or clinic 786 (18.5) 122 (8.8)
Duration of hospital 
stay following index 
stroke
<0.001
≤16 days 2,389 (56.2) 624 (45.0)
>16 days 1,865 (43.8) 762 (55.0)
Note: Data presented as n (%) or medians (IQRs).
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use exhibited lower risk of hospitalization and vital-organ 
failure in COPD patients.50,51
Despite the promising reports from animal and observa-
tional studies, there are conflicting data from clinical trials on 
the relationship between statin therapy and risk of pneumonia. 
A meta-analysis that included eleven randomized trials on use 
of statins found no significant preventive effect of the drug on 
the risk of infection.52 Similarly, a recent meta-analysis that 
included five clinical trials with 8,791 stroke or transient 
ischemic–attack patients did not report a significant effect of 
statins on reduction in risk of infection.53 Based on these 
negative findings, there is a concern for potential bias in 
observational studies suggesting the preventive effect of sta-
tins in pneumonia.54,55 Treatment with statins may reflect the 
willingness of the patient to follow treatment and better func-
tional status (healthy-user effects), rather than the true biolo-
gical preventive effect of the drug.10 However, caution must 
be exercised in interpretation of the negative findings of the 
clinical trials, because none of the trials set pneumonia as the 
primary outcome measure. The randomized, double-blind, 
placebo-controlled JUPITER trialdocumented that the rosu-
vastatin group had a lower risk of pneumonia than the placebo 
group.26
In the present study, the preventive effect of statins 
remained unchanged after additional adjustment for treat-
ment with antihypertensive medications. This finding sug-
gested that the preventive effect of treatment with statins 
was not completely explained by compliance with medical 
treatment. The conflicting data among studies might be 
related to heterogeneous regimens, timing of treatment 
with statins, variability in definition of pneumonia, and 
study duration.56 Patients with acute ischemic stroke in 
the present study, who were particularly at great risk for 
pneumonia, may be more likely to benefit from treatment 
with statins than the general population. To date, no large 
randomized clinical study has been conducted evaluating 
the effect of statins on the development of pneumonia as 
the primary outcome measure. Further evidence based on 
well-designed prospective randomized trials is needed to 
address the key question of the beneficial role of statins in 
pneumonia.8
In accordance with the initial expectation, we found 
a dose-dependent relationship between risk of pneumonia 
and intensity of statins. Along with lipid-lowering potency, 
the beneficial pleiotropic effects of statins, such as the 
antibacterial and immunomodulatory properties, may act 
















































Figure 3 Estimated pneumonia-free probability according to treatment with statins (A) and according to intensity of statins (B) during follow-up. HRs for pneumonia and 
95% CIs were derived from the univariate time-dependent Cox proportional hazard–regression model.
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in a dose-dependent fashion.57 To maximize the potential 
benefits of statins, further experimental and clinical inves-
tigations are warranted to elucidate the underlying biolo-
gical mechanism of action of statins in pneumonia.
The main strength of the current study is the use of 
information from the population-based random-sampling 
database, which enabled inclusion of >7,000 subjects with 
acute ischemic stroke. Based on the national database, 
longitudinal follow-up of the participants to assess the occur-
rence of pneumonia was possible. Unlike prior studies, which 
have focused mainly on exposure to statins before or during 
the early phase of admission following a stroke, data 
on treatment with statins throughout follow-up after dis-
charge from hospital were collected in the current study, 
reflecting dynamic changes in medications in clinical prac-
tice. The potential limitations of this study should also be 
acknowledged. Clinical data regarding stroke severity, func-
tional disability, dysphagia, smoking, and lipid levels were 
not obtained, owing to unavailability of such information 
from the health-insurance database. Due to the retrospective 
observational design of the study, causality between statin 
use and risk of pneumonia could not be established. Data on 
statin use was obtained from the prescription records of each 
subject. There may be a gap between prescribed medication 
and actual medicine-taking behaviors of subjects. Previous 
research has shown a good association between values cal-
culated from prescription records and real intake of 
medications.58 In the current study, detection of pneumonia 
outcome was based on ICD10 codes, which may be asso-
ciated with loss of subjects with pneumonia by error of 
registration in clinical practice or by them missing hospital 
visits. Moreover, the ICD10 codes J09–J18 can overestimate 
pneumonia diagnosis, since suspected diagnoses can also be 
labeledICD10 J09–J18 in real-world practice. The current 
study was performed using data of Asian subjects with 
acute ischemic stroke. Further studies must be conducted to 
evaluate the general applicability of the results in different 
ethnicities and disease populations.
Conclusion
Using a national health-insurance database, the current 
study found reduced risk of poststroke pneumonia with 
statin therapy after acute ischemic stroke. The preventive 
effect of statins on pneumonia did not differ based on 
statin intensity. Encouragement of statin treatment after 
ischemic stroke, the guideline-recommended treatment, 
may reduce poststroke pneumonia, which is a common 
and critical illness in stroke subjects.
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Sex, male 0.95 (0.86–1.04) 1.18 (1.07–1.31)
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Note: Data derived from multivariate time-dependent Cox proportional hazard– 
regression model adjusted for the variables listed in Table 3.
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